CLINICAL TRIALS: New nonabsorbable potassium-exchange resins in hyperkalaemia

    loading  Checking for direct PDF access through Ovid

Abstract

New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks reduces plasma potassium levels in hyperkalaemic patients. If proven safe and effective for long-term use, these therapies might be administered together with intensive renin-angiotensin-aldosterone blockade to reduce adverse effects and renal and cardiovascular risk.

Related Topics

    loading  Loading Related Articles